Pharming Group
PHAR
3 hedge funds and large institutions have $216K invested in Pharming Group in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
8% less capital invested
Capital invested by funds: $234K → $216K (-$18.5K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$615 |
Top Sellers
PHAR Hedge Fund Activity: Q1 2024 in Review
3 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q1 2024, worth a combined $216K — down 7.9% from $234K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PHAR positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $615.
- 3 institutional investors held Pharming Group (PHAR) as of Q1 2024, up from 2 in Q4 2023.
- Funds reported $216K of Pharming Group stock for Q1 2024, down 7.9% quarter-over-quarter.
- 1 fund opened new Pharming Group positions in Q1 2024 and 0 closed out, a net change of +1 holder.
- The largest Pharming Group buyer in Q1 2024 was UBS Group, an estimated $615 added.
Based on aggregated 13F filings for Q1 2024.